| Name | Title | Contact Details |
|---|
Global Health Strategies (GHS) is an international consulting company that specializes in global health communications, advocacy, research and strategy. We focus on public health issues that impact developing nations and emerging markets. Our clients include leading foundations, industry, NGOs, government agencies, academic institutions and product development. Our work is driven by a passion for improving the health and wellbeing of individuals and communities around the world. We offer the skills, knowledge and goal-driven efficiency to enhance our clients` efforts to address some of the world’s toughest health challenges, including HIV/AIDS, tuberculosis, malaria, polio eradication, sexual and reproductive health and vaccines. GHS has offices in New York, New Delhi, Rio de Janeiro and Beijing, and supports work in countries in Africa, Asia, Europe and the Americas.
AIM Specialty Health® provides clinical solutions that drive appropriate, safe, and affordable care. Serving more than 50 million members across 50 states, D.C. and US territories, AIM promotes optimal care through use of evidence-based clinical guidelines and real-time decision support for both providers and their patients. The AIM platform delivers significant cost of care savings across an expanding set of clinical domains including radiology, cardiology, oncology, specialty drugs, sleep medicine, musculoskeletal, pain management, and genetic testing. AIM is a wholly-owned subsidiary of Anthem, Inc. (ANTM).
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.
US HealthConnect is a Fort Washington, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ayurveda Plus is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.